Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11535670 Combination therapies of HDAC inhibitors and PD-L1 inhibitors

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

December 27, 2022

Patent Application Number

16541020

Date Filed

August 14, 2019

Patent Citations

US Patent 10287353 Combination therapies of HDAC inhibitors and PD-1 inhibitors

US Patent 10385131 Combination therapies of HDAC inhibitors and PD-L1 inhibitors

US Patent 10017492 Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof

US Patent 10385130 Combination therapies of HDAC inhibitors and PD-1 inhibitors

Patent Primary Examiner

CPC Code

Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11535670 Combination therapies of HDAC inhibitors and PD-L1 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool